The downgrade from Overweight to Neutral by a prominent analyst, along with a drastic reduction in the price target, is likely to negatively impact investor sentiment and the stock price of Achilles Therapeutics in the short term. Such analyst actions often lead to immediate market reactions, as they are seen as a significant change in the stock's outlook.